The authors wish to make the following corrections to this paper [1].
The authors have made a critical typing error and a counting error in Table 2 as the parameters of “Community-acquired infection” and “Healthcare-associated infection” were mistakenly switched with each other.
Accordingly, Table 2, which is shown as follows:
should be replaced with the following:
Table 2.
Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
Table 2.
Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
| Characteristics | All (n = 92) | Number of Episodes (%) | OR (95% CI) | p-Value | |
|---|---|---|---|---|---|
| E. meningoseptica (n = 20) | E. anophelis (n = 72) | ||||
| Sex | |||||
| Male | 64 (69.6) | 15 (75) | 49 (68.1) | 1.41 (0.46–4.35) | 0.55 |
| Female | 28 (30.4) | 5 (25) | 23 (31.9) | 0.71 (0.23–2.19) | 0.55 |
| Age | |||||
| Range (year) | 3–89 | 18–80 | 3–89 | ||
| Median (year) | 61 | 61 | 62.5 | ||
| Mean ± standard deviation (year) | 61.1 ± 17 | 56.6 ± 15.6 | 62.4 ± 17.3 | 0.179 | |
| Comorbidity | |||||
| Diabetes mellitus | 24 (26.1) | 6 (30) | 18 (25) | 1.29 (0.43–3.84) | 0.652 |
| Hypertension | 26 (28.3) | 4 (20) | 22 (30.6) | 0.57 (0.17–1.9) | 0.354 |
| End-stage renal disease | 5 (5.4) | 1 (5) | 4 (5.6) | 0.9 (0.09–8.49) | 0.999 |
| Malignancy | 40 (43.5) | 8 (40) | 32 (44.4) | 0.83 (0.3-2.28) | 0.723 |
| Liver cirrhosis | 8 (8.7) | 3 (15) | 5 (6.9) | 2.37 (0.51–10.89) | 0.365 |
| Chronic obstructive pulmonary disease | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
| Type of infection acquisition | |||||
| Community-acquired infection | 10 (10.9) | 20 | 63 (87.5) | 0.197 | |
| Healthcare-associated infection | 82 (89.1) | 0 | 9 (12.5) | 0.197 | |
| Laboratory data | |||||
| White blood cell count (cells/mm3) | 13,281 ± 8740 | 13,353 ± 6687 | 13,261 ± 9271 | 0.967 | |
| Hemoglobin (g/dL) | 10.1 ± 2.1 | 9.8 ± 2.4 | 10.1 ± 2.1 | 0.585 | |
| Platelet count (×1000 cells/mm3) | 228,570 ± 131,056 | 216,550 ± 157,332 | 231,900 ± 123,846 | 0.69 | |
| Serum creatinine (mg/dL) | 1.8 ± 1.7 | 1.6 ± 1.3 | 1.9 ± 1.8 | 0.584 | |
| Empirical antimicrobial therapy | |||||
| β-lactams | 41 (44.6) | 11 (55) | 30 (41.7) | 1.71 (0.63–4.64) | 0.289 |
| β-lactam/lactamase inhibitors | 20 (21.7) | 4 (20) | 16 (22.2) | 0.88 (0.26–2.99) | 0.999 |
| Ciprofloxacin | 10 (10.9) | 1 (5) | 9 (12.5) | 0.37 (0.04–3.1) | 0.685 |
| Levofloxacin | 24 (26.1) | 1 (5) | 23 (31.9) | 0.11 (0.01–0.89) | 0.015 |
| Carbapenems | 17 (18.5) | 4 (20) | 13 (18.1) | 1.14 (0.33–3.96) | 0.999 |
| Aminoglycosides | 9 (9.8) | 3 (15) | 6 (8.3) | 1.94 (0.44–8.57) | 0.402 |
| Tigecycline | 8 (8.7) | 2 (10) | 6 (8.3) | 1.22 (0.23–6.58) | 0.999 |
| Colistin | 6 (6.5) | 1 (5) | 5 (6.9) | 0.71 (0.08–6.41) | 0.999 |
| Inappropriate empirical antimicrobial therapy | 74 (80.4) | 20 (100) | 54 (75) | 0.01 | |
| Shock | 42 (45.7) | 9 (45) | 33 (45.8) | 0.97 (0.36–2.62) | 0.999 |
| Admission to intensive care unit | 44 (47.8) | 9 (45) | 35 (48.6) | 0.87 (0.32–2.34) | 0.775 |
| Case fatality | 25 (27.2) | 6 (30) | 19 (26.4) | 1.2 (0.4–3.56) | 0.748 |
Abbreviations: OR, odds ratio; CI, confidence interval.
Table 2.
Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
Table 2.
Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
| Characteristics | All (n = 92) | Number of Episodes (%) | OR (95% CI) | p-Value | |
|---|---|---|---|---|---|
| E. meningoseptica (n = 20) | E. anophelis (n = 72) | ||||
| Sex | |||||
| Male | 64 (69.6) | 15 (75) | 49 (68.1) | 1.41 (0.46–4.35) | 0.55 |
| Female | 28 (30.4) | 5 (25) | 23 (31.9) | 0.71 (0.23–2.19) | 0.55 |
| Age | |||||
| Range (year) | 3–89 | 18–80 | 3–89 | ||
| Median (year) | 61 | 61 | 62.5 | ||
| Mean ± standard deviation (year) | 61.1 ± 17 | 56.6 ± 15.6 | 62.4 ± 17.3 | 0.179 | |
| Comorbidity | |||||
| Diabetes mellitus | 24 (26.1) | 6 (30) | 18 (25) | 1.29 (0.43–3.84) | 0.652 |
| Hypertension | 26 (28.3) | 4 (20) | 22 (30.6) | 0.57 (0.17–1.9) | 0.354 |
| End-stage renal disease | 5 (5.4) | 1 (5) | 4 (5.6) | 0.9 (0.09–8.49) | 0.999 |
| Malignancy | 40 (43.5) | 8 (40) | 32 (44.4) | 0.83 (0.3-2.28) | 0.723 |
| Liver cirrhosis | 8 (8.7) | 3 (15) | 5 (6.9) | 2.37 (0.51–10.89) | 0.365 |
| Chronic obstructive pulmonary disease | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
| Type of infection acquisition | |||||
| Community-acquired infection | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
| Healthcare-associated infection | 83 (90.2) | 20 | 63 (87.5) | 0.197 | |
| Laboratory data | |||||
| White blood cell count (cells/mm3) | 13,281 ± 8740 | 13,353 ± 6687 | 13,261 ± 9271 | 0.967 | |
| Hemoglobin (g/dL) | 10.1 ± 2.1 | 9.8 ± 2.4 | 10.1 ± 2.1 | 0.585 | |
| Platelet count (×1000 cells/mm3) | 228,570 ± 131,056 | 216,550 ± 157,332 | 231,900 ± 123,846 | 0.69 | |
| Serum creatinine (mg/dL) | 1.8 ± 1.7 | 1.6 ± 1.3 | 1.9 ± 1.8 | 0.584 | |
| Empirical antimicrobial therapy | |||||
| β-lactams | 41 (44.6) | 11 (55) | 30 (41.7) | 1.71 (0.63–4.64) | 0.289 |
| β-lactam/lactamase inhibitors | 20 (21.7) | 4 (20) | 16 (22.2) | 0.88 (0.26–2.99) | 0.999 |
| Ciprofloxacin | 10 (10.9) | 1 (5) | 9 (12.5) | 0.37 (0.04–3.1) | 0.685 |
| Levofloxacin | 24 (26.1) | 1 (5) | 23 (31.9) | 0.11 (0.01–0.89) | 0.015 |
| Carbapenems | 17 (18.5) | 4 (20) | 13 (18.1) | 1.14 (0.33–3.96) | 0.999 |
| Aminoglycosides | 9 (9.8) | 3 (15) | 6 (8.3) | 1.94 (0.44–8.57) | 0.402 |
| Tigecycline | 8 (8.7) | 2 (10) | 6 (8.3) | 1.22 (0.23–6.58) | 0.999 |
| Colistin | 6 (6.5) | 1 (5) | 5 (6.9) | 0.71 (0.08–6.41) | 0.999 |
| Inappropriate empirical antimicrobial therapy | 74 (80.4) | 20 (100) | 54 (75) | 0.01 | |
| Shock | 42 (45.7) | 9 (45) | 33 (45.8) | 0.97 (0.36–2.62) | 0.999 |
| Admission to intensive care unit | 44 (47.8) | 9 (45) | 35 (48.6) | 0.87 (0.32–2.34) | 0.775 |
| Case fatality | 25 (27.2) | 6 (30) | 19 (26.4) | 1.2 (0.4–3.56) | 0.748 |
Abbreviations: OR, odds ratio; CI, confidence interval.
The authors apologize for any inconvenience caused to the readers by these changes.
Reference
- Lin, J.-N.; Lai, C.-H.; Yang, C.-H.; Huang, Y.-H. Comparison of clinical manifestations, antimicrobial susceptibility patterns, and mutations of fluoroquinolone target genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis isolated in Taiwan. J. Clin. Med. 2018, 7, 538. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).